By David E. Gerber, MD Posted: November 12, 2019 Dr. David E. Gerber The underlying concept for antibody–drug conjugates (ADCs) is relatively straightforward: capitalize on the highly specific targeting of […] Read more
PROVIDER RESOURCES
MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC
INDUSTRY SUPPORTED
COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events